List of companies in MRL Ventures's investment portfolio
Name | Description | Industry | Official Website | Location | ||
|---|---|---|---|---|---|---|
A company developing antibody-based biological medicines for kidney diseases and other chronic diseases. Visterra was acquired by Otsuka Pharmaceutical in 2018. | ||||||
A biopharmaceutical company that develops treatments for multi-drug resistant (MDR) bacterial infection | ||||||
A therapeutics company founded in 2016 working in drug discovery and development using fungi. LifeMine uses genomics approaches to search for biosynthetic genes in eukaryotic microbes for the discovery of naturally inspired drugs to treat previously untreatable and significant chronic diseases. | ||||||
Translate Bio is a clinical-stage mRNA therapeutics company developing medicines to treat diseases caused by protein or gene dysfunction and vaccines against infectious disease pathogens. | ||||||
Adagio Therapeutics is a Waltham, Massachusetts-based biotechnology company involved in the research and development of therapeutic pharmaceuticals. | ||||||
Rheostat, located at 300 Technology Square, in Cambridge, Massachusetts is a biotech company developing treatments for neurodegenerative diseases by targeting mitophagy and autophagy pathways. | ||||||
Kymera Therapeutics is a Cambridge, Massachusetts-based biotechnology company specialized in the field of targeted protein degradation. | ||||||
Carisma Therapeutics is a biotechnology company founded in 2016 to bring the potheyr of adoptive cellular immunotherapy to solid tumor patients through a novel platform using chimeric antigen receptor macrophages (CARMA). | ||||||
Alector is a San Francisco, California biotechnology company developing treatments for neurodegeneration and cancer through immuno-neurology and immuno-oncology. | ||||||
Imago BiosSciences is a clinical-stage therapeutics company developing treatments for malignant and life-threatening diseases for bone marrow. | ||||||
Biotechnology company developing medicines that target allosteric regulatory sites on proteins | ||||||
Xilio Therapeutics is a cancer Immunotherapies founded in 2016 by Rene Russo. | ||||||
Entrada Therapeutics is a biologics delivered to cytosol founded in 2016. | ||||||
Lava Therapeutics is a biotechnology research company developing bispecific gamma-delta T cell engaging (bsTCE) antibodies to fight cancer. | ||||||
Aktis Oncology is a biotechnology company discovering and developing a novel class of targeted radiopharmaceuticals. | ||||||
PAQ Therapeutics is a biotechnology company developing autophagy-based therapies. | ||||||
Small molecule cancer drugs that stabilize the direct interaction of oncogenic proteins with the 14-3-3 class of adaptor proteins | ||||||
Therini Bio specializes in fibrin-targeting therapies to treat inflammatory neurological and retinal diseases. | ||||||
Antibody therapies developer for oncology and auto-immune disease. | ||||||
Tallac Therapeutics is a novel Cancer Immunotherapies. | ||||||
Mozart Therapeutics is a Seattle-based company. | ||||||
Photys Therapeutics is a Cambridge, Massachusetts-based company. | ||||||
Viridian Therapeutics, Inc. is a Waltham, Massachusetts-based company founded in 2020. |
